Godavari Drugs Ltd
Pharmaceuticals
FV – Rs 10; 52wks H/L – 54.9/34; TTQ – 1243; CMP – Rs 42 (As On May 22, 2017);
Market Cap – Rs 32Crs
Standalone Financials and Valuations for FY16 (Amt in Rs Crs unless specified)
Equity Capital |
Net worth |
Long Term Debt | Total Sales |
PAT | BV (Rs) |
EPS (Rs) |
P/E |
Industry P/E |
P/BV |
Promoter’s Stake |
Beta |
| 7.53 | 15 | 4 | 71 | 1.35 | 20 | 1.79 | 23.46 | 29.41 | 2.1 | 49.91 | 1.66 |
Standalone Financials and Valuations for 9Mnths FY17
Equity Capital |
Net worth |
Long Term Debt | Total Sales |
PAT | BV (Rs) |
TTM EPS (Rs) |
P/E |
Industry P/E |
P/BV |
Promoter’s Stake |
Beta |
| 7.53 | 17 | 4 | 65 | 1.22 | 23 | 1.62 | 25.93 | 29.41 | 1.83 | 49.91 | 1.66 |
Valuation Parameters:
- Long Term Debt to Equity – 0.3
- ROE % – 9
- Market Cap/Sales – 0.5
Overview:
- Godavari Drugs Ltd is engaged in the contract manufacturing, loan license manufacturing, manufacturing and supply of active pharmaceutical ingredients (APIs), drug intermediaries and fine chemicals.
- The Company’s API products include Ciprofloxacin Hydrochloride, Enrofloxacin, Centrizine Hydrochloride and Ethambutol Hydrochloride.
- Its intermediate products include A D Lactone and Benzhyryl Piperazine.
- Its manufacturing facilities are located at Maharashtra Industrial Development Corporation estate at Nanded, Maharashtra, India.
- The manufacturing facilities are equipped with glass lined reactors, stainless steel reactors, filtration equipment of various types, drying equipment of various types, compaction facilities, solvent recovery and rectification facilities, hydrogenation facilities suitable for high pressures up to 45 bar, vapor phase catalytic tube reactors operable at temperatures in the range of 450 degrees centigrade, distillative reaction facilities and others.
Management:
- Ghanshyam Jaju – Chairman
- Mukund Kakani – MD
- Kirti Kumar Jain – CFO
The Equity Capital is @ Rs 7.53 Crs consisting of 7530500 equity Shares of FV Rs 10 currently held as under
10.48% Of the Promoter’s Holding is pledged.
Major Non – Promoter Holdings:
| Non – Promoters | No. of shares held | % of shares held |
| Kewal Goel | 148700 | 1.97 |
| Pawan Kothari | 98198 | 1.3 |
| Anuradha Karanjgaokar | 100000 | 1.33 |
| Vrunda Karanjgaokar | 100000 | 1.33 |
| Varun Jain | 100000 | 1.33 |
| Ashwini Karanjgaokar | 100000 | 1.33 |
| Karanjgaokar | 80000 | 1.06 |
Standalone Financial Trends (In Rs. Crs) :
| Particulars | FY16 | FY15 | FY14 | FY13 | FY12 |
| Equity Paid Up | 7.53 | 7.53 | 7.53 | 7.53 | 7.53 |
| Networth | 15 | 14 | 10 | 8 | 7 |
| Total Debt | 16 | 9 | 2 | 3 | 2 |
| Net Sales | 71 | 55 | 9 | 8 | 4 |
| Other Income | 0.2 | 0 | 0 | 0 | 0 |
| PAT | 1.35 | 3.85 | 1.55 | 0.48 | -1.6 |
| Book Value (Rs) | 20 | 19 | 13 | 11 | 9 |
| EPS (Rs) | 1.79 | 5.11 | 2.06 | 0.64 | -2.12 |
